Core Viewpoint - The article discusses the discovery of novel micropeptides in human gastric cancer tissues, highlighting their potential as therapeutic targets and the role of artificial intelligence in their functional annotation [2][5]. Group 1: Discovery of Micropeptides - A research team from Zhejiang University identified nearly ten thousand novel micropeptides in human gastric cancer tissues, suggesting that these previously underexplored proteins may hold keys to treating various diseases, including cancer [2]. - The study challenges the traditional binary classification of coding and non-coding genes, showcasing the significant potential of the non-canonical proteome in cancer biology research [3]. Group 2: Functional Characterization of Micropeptides - The team focused on liver cancer-related micropeptides, revealing that a specific micropeptide, MRPIP, regulates mitochondrial RNA processing and energy metabolism, thereby inhibiting liver cancer proliferation [5][12]. - MRPIP was found to be significantly downregulated in liver cancer tissues and associated with poor prognosis, indicating its potential as a biomarker [9]. Group 3: Mechanistic Insights - The research demonstrated that MRPIP interacts with the mitochondrial RNA processing complex, disrupting its assembly and affecting mitochondrial RNA processing and protein translation, which ultimately suppresses tumor growth [12]. - The transcription factor FOXO1 was shown to upregulate MRPIP under glucose starvation conditions, linking energy stress responses to mitochondrial translation regulation [12]. Group 4: Development of Therapeutic Candidates - Based on the functional insights of MRPIP, the team synthesized a 20-amino acid micropeptide drug precursor, PMHR, which effectively inhibits liver cancer progression by targeting mitochondrial translation and energy metabolism [13]. - The study provides a new strategy for developing targeted therapies based on endogenous bioactive small molecules [15]. Group 5: Data Accessibility and Future Research - The identified micropeptides and related data are included in the Human Micropeptide Atlas (HMPA), a visual dataset that integrates clinical data and micropeptide information from various cancers, facilitating further research in precision medicine [16].